LES PUBLICATIONS. Belouzard S. Mécanismes d entrée des coronavirus. Virologie, 2010, 14:1-15.
|
|
- Laurence Craig
- 8 years ago
- Views:
Transcription
1 LES PUBLICATIONS MOLECULAR AND CELLULAR VIROLOGY OF HEPATITIS Inserm U CNRS UMR 8204 University Lille 1 - University Lille 2 Institut Pasteur de Lille affiliated to IFR 142 Responsable Jean DUBUISSON Ahmed-Belkacem A, Ahnou N, Barbotte L, Wychowski C, Pallier C, Brillet R, Pohl RT, Pawlotsky JM. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology, 2010, 38: Belouzard S. Mécanismes d entrée des coronavirus. Virologie, 2010, 14:1-15. Belouzard S, Madu I, Whittaker GR. Elastase activation of the SARS coronavirus spike protein at discrete sites within S2 domain. J Biol Chem, 285: Ciczora I, Callens N, Séron K, Rouillé Y, Dubuisson J. Identification of a dominant endoplasmic reticulum retention signal in yellow fever virus pre-membrane protein. J Gen Virol, 2010, 91: Goueslain L, Alsaleh K, Horrelou P, Roingeard P, Descamps V, Duverlie G, Ciczora Y, Wychowski C, Dubuisson J, and Rouillé Y. Identification of GBF1 as a cellular factor required for HCV RNA replication. J Virol, 2010, 84: Helle F, Vieyres G, Elkrief L, Popescu I, Wychowski C, Descamps V, Castelain S, Duverlie G, Dubuisson J. Role of N-linked glycans in the functions of HCV envelope proteins incorporated into infectious virions. J Virol, 2010, in press. Montserret R, Saint N, Vanbelle C, Salvay A, Simorre JP, Ebel C, Sapay N, Renisio JG, Böckmann A, Steinmann E, Pietschmann T, Dubuisson J, Chipot C, Penin F. NMR structure analysis and ion channel activity of the p7 polypeptide from hepatitis C virus. J Biol Chem, 2010, in press. Pawlotsky JM, Cocquerel L, Durantel D, Lavillette D, Lerat H, Pécheur EI, Polyak SJ, Tautz N, Thimme R. HCV research 20 years after discovery : a summary of the 16th international meeting on hepatitis c virus and related viruses. Gastroenterology, 2010, 138:6-12. Popescu CI, Dubuisson J. Role of lipid metabolism in hepatitis C virus assembly and entry. Biol Cell, 2010, 102: Tews B, Popescu CI, Dubuisson J. Last stop before exit Hepatitis C assembly and release as antiviral drug targets. Viruses, 2010, 2: Vieyres G, Thomas X, Descamps V, Duverlie G, Patel AH, Dubuisson J. Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J Virol, 2010, 84:
2 2009 Alvarez-Lajonchere L, Shoukry N, Gra B, Amado-Canizares Y, Helle F, Bedard N, Guerra I, Drouin C, Dubuisson J, Gonzalez Horta EE, Martinez G, Marante J, Cinza Z, Castellanos M, Duenas-Carrera S. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a phase I clinical trial. J Viral Hepatitis, 2009, 16: Charrin S, Yalaoui S, Bartosch B, Cocquerel L, Franetich JF, BoucheixC, Mazier D, Rubinstein E, Silvie O. The IG domain protein CD9P-1 down-regulates CD81 ability to support plasmodium YOELII infection. J Biol Chem, 2009, 284: Dubois A, Francois C, Descamps V, Fournier C, Wychowski C, Dubuisson J, Castelain S, Duverlie G. Enhanced anti-hcv activity of interferon alpha 17 subtype. Virol J, 2009, 6:70. Helle F, Dubuisson J. Rôle des N-glycanes dans les fonctions des protéines d enveloppe du virus de l hépatite C. Virologie, 2009, 13: Kuzmina TI, Olenina LV, Sanzhakov MA, Farafonova TE, Abramihina TV, Dubuisson J, Sobolev BN, Kolesanova EF. Antigenicity and B-epitope mapping of hepatitis C virus envelope protein E2. Biomed Chem (Moscow), 2009, 55: Rocha-Perugini V, Lavie M, Delgrange D, Canton J, Pillez A, Potel J, Lecoeur C, Rubinstein E, Dubuisson J, Wychowski C, Cocquerel L. The association of CD81 with tetraspanin-enriched microdomains is not essential for Hepatitis C Virus entry. BMC Microbiol, 2009, 9:111. Roohvand F, Maillard P, Lavergne JP, Boulant S, Walic M, Andréo U, Goueslain L, Helle F, McLauchlan J, Budkowska A. Initiation of hepatitis C virus infection requires the dynamic microtubule network: Role of the viral nucleocapsid protein. J Biol Chem, 2009, 284: Tews BA, Cocquerel L. Occludin, an additional key for hepatitis C virus entry. Med Sci (Paris), 2009, 25: Tews BA, Dubuisson J. Occludin, the final essential factor for HCV entry? Future Virology, 2009, 4: Touvier T, Conte-Auriol F, Briand O, Cudejko C, Paumelle R, Caron S, Baugé E, Rouillé Y, Salles JP, Staels B, Bailleul B. LEPROT and LEPROTL1 cooperatively decrease hepatic growth hormone action in mice. J Clin Invest, 2009, 119 : Vieyres G, Angus AG, Haberstroh A, Baumert TF, Dubuisson J, Patel AH. Rapid synchronization of hepatitis C virus infection by magnetic adsorption. J Virol Methods, 2009, 157(1): Castelain S, Schnuriger A, François C, Nguyen-Khac E, Fournier C, Schmit JL, Capron D, Dubuisson J, Wychowski C, Thibault V, Duverlie G. Lower levels of HCV neutralizing antibodies in HIV/HCV-coinfected patients than in HCV-monoinfected patients. J Infect Dis, 2008, 198 : Dubuisson J, Helle F, Cocquerel L. Early steps of the Hepatitis C Virus life cycle. Cell Microbiol, 2008, 10:
3 Helle F, Dubuisson J. Hepatitis C Virus entry into host cells. Cell Mol Life Sci, 2008, 65: Helle F, Dubuisson J. Mechanism and inhibition of Hepatitis C Virus entry. J Viral Entry, 2008, 3: Helle F, Cocquerel L. L entrée du virus de l hépatite C dans ses cellules cibles. Virologie, 2008, 12: Jaffrelo L, Chabas S, Reigadas S, Pflieger A, Wychowski C, Rumi J, Ventura M, Toulmé JJ, Staedel C. A functional selection of viral genetic elements in cultured cells to identify hepatitis C virus RNA translation inhibitors. Nucleic Acids Res, 2008, 36:e95. Machida K, Kondo Y, Huang J, Chen YC, Cheng KTH, Keck Z, Foung S, Dubuisson J, Sung VMH, Lai MMC. HCV-induced Immunoglobulin Hypermutation Reduces the Affinity and Neutralizing Activities of Antibodies against HCV Envelope Protein. J Virol, 2008, 82: Molina S, Castet V, Pichard-Garcia L, Wychowski C, Meurs E, Pascussi JM, Sureau C, Fabre JM, SaCunha A, Larrey D, Dubuisson J, Coste J, McKeating J, Maurel P, Fournier-Wirth C. Serum derived HCV infection of primary human hepatocytes is tetraspanin CD81 dependent. J Virol, 2008, 82: Rocha-Perugini V, Montpellier C, Delgrange D, Wychowski C, Helle F, Pillez A, Drobecq H, Le Naour F, Charrin S, Levy S, Rubinstein E, Dubuisson J, Cocquerel L. The CD81 partner EWI-2wint inhibits hepatitis C virus entry. PLoS ONE 3, 2008, e1866. Voisset C, Lavie M, Helle F, Op De Beeck A, Bilheu A, Bertrand-Michel J, Tercé F, Cocquerel L, Wychowski C, Vu-Dac N, Dubuisson J. Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits HCV entry. Cell Microbiol, 2008, 10: Voisset C, Weiss RA, Griffiths DJ. Human RNA "rumor" viruses : the search for novel human retroviruses in chronic disease. Microbiol Mol Biol Rev, 2008, 72: Antoine AF, Montpellier C, Cailliau K, Browaeys-Poly E, Vilain JP, Dubuisson J. The Alphavirus 6K protein activates endogenous ionic conductances when expressed in Xenopus oocytes. J Membr Biol, 2007, 215: Akazawa D, Date T, Morikawa K, Murayama A, Miyamoto M, Kaga M, Barth H,. Baumert T, Dubuisson J, Wakita T. CD81 expression is important for heterogeneous HCV permissiveness of Huh7 cell clones. J Virol, 2007, 81, Brochot E, Duverlie G, Castelain S, Morel V, Wychowski C, Dubuisson J, François C. Effect of ribavirin on the hepatitis C virus (JFH-1) and its correlation with interferon sensitivity. Antivir Ther, 2007, 12: Castelain S, Bonte D, Penin F, Francois C, Capron D, Dedeurwaerder S, Zawadzki P, Morel V, Wychowski C, Duverlie G. Hepatitis C Virus p7 membrane protein quasispecies variability in chronically infected patients treated with interferon and ribavirin, with or without amantadine. J Med Virol, 2007, 79:
4 Chapel C, Garcia C, Bartosh B, Roingeard P, Zitzmann N, Cosset FL, Dubuisson J, Dwek RA, Trépo C, Zoulim F, Durantel D. Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors. J Gen Virol, 2007, 88: Chevalier C, Saulnier A, Benureau Y, Flechet D, Delgrange D, Colbere-Garapin F, Wychowski C, Martin A. Inhibition of Hepatitis C Virus Infection in Cell Culture by Small Interfering RNAs. Mol Ther, 2007, 15: Ciczora Y, Callens N, Penin F, Pécheur EI, Dubuisson J. The transmembrane domains of HCV envelope glycoproteins: residues involved in E1E2 heterodimerization and involvement of these domains in virus entry. J Virol, 2007, 81: Couturier C, Sarkis C, Séron K, Belouzard S, Chen P, Lenain A, Corset L, Dam J, Vauthier V, Dubart A, Mallet J, Froguel P, Rouillé Y, Jockers R. Silencing of OB-RGRP in mouse hypothalamic arcuate nucleus increases leptin receptor signaling and prevents dietinduced obesity. Proc Natl Acad Sci USA, 2007, 104: Delgrange D, Pillez A, Castelain S, Cocquerel L, Rouillé Y, Dubuisson J, Wakita T, Duverlie G, Wychowski C. Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins. Gen Virol, 2007, 88: Dubuisson J. Hepatitis C virus proteins. World J Gastroenterol, 2007, 13: Duverlie G, Wychowski C. Cell culture systems for the hepatitis C virus. World J Gastroenterol, 2007, 13: Fournier C, Duverlie G, Francois C, Schnuriger A, Dedeurwaerder S, Brochot E, Capron D, Wychowski C, Thibault V, Castelain S. A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies. Virol J, 2007, 4:35. Gatignol A, Dubuisson J, Wainberg MA, Cohen EA, Jean-Luc Darlix JL. New pandemics: HIV and AIDS, HCV and chronic hepatitis, Influenza virus and flu. Retrovirology, 2007, 4:8. Helle F, Goffard A, Morel V, Duverlie G, McKeating J, Keck ZY, Foung S, Penin F, Dubuisson J, Voisset C. The neutralizing activity of anti-hcv antibodies is modulated by specific glycans on the E2 envelope protein. J Virol, 2007, 81: Johansson DX, Voisset C, Tarr AW, Aung M, Ball JK, Dubuison J, Persson M. Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc Natl. Acad Sci USA, 2007, 104: Lavie M, Goffard A, Dubuisson J. Assembly of a functional HCV glycoprotein heterodimer. Curr Issues Mol Biol, 2007, 9: PhD François HELLE Directeur de thèse : J Dubuisson "Les N-glycanes du Virus de l'hépatite C protègent contre la neutralisation mais sont une cible thérapeutique potentielle" 27 septembre 2007
5 David DELGRANGE Directeur de thèse : C Wychowski "Etude de la multiplication de la souche JFH-1 du virus de l hépatite C (VHC) en cellules Huh-7. Adaptation et sélection de mutations permettant une production rapide et massive du VHC. Localisation subcellulaire de protéines du VHC. Mise en évidence de clones cellulaires résistants à l infection par le VHC" 21 septembre 2007 Vera ROCHA Directeur de thèse : L Cocquerel "Identification d EWI-2wint, un partenaire de CD81 qui inhibie l entrée du VHC" 26 septembre 2007 HDR Ngoc VU-DAC "Rôle des lipoprotéines, transfert lipidique et mécanismes d entrée du VHC dans les hépatocytes" Laurence COQUEREL "Identification et caractérisation d'un inhibiteur de l entrée du virus de l'hépatite C" Karin SERON "Etude de différents aspects du trafic membranaire : de la levure Saccharomyces cerevisiae à l'obésité humaine"
The autophagy machinery is required to initiate hepatitis C virus infection. Marlène Dreux
The autophagy machinery is required to initiate hepatitis C virus infection Marlène Dreux Hepatitis C virus life cycle HCV particles internalization RNA replication RNA translation ER HCV assembly and
More informationProspects for Vaccines against Hepatitis C Viruses. T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS
Prospects for Vaccines against Hepatitis C Viruses T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS HCV Vaccine Prevention strategies Protective immunity Barriers and solutions Vaccine candidates
More informationAUCUN CONFLIT D'INTERET
Lysophosphatidylcholine acyltransferase 1 () is downregulated by hepatitis C virus: impact on production of lipo-viro-particles Matthieu LEMASSON, Frauke BEILSTEIN, Véronique PENE, Sylvie DEMIGNOT & Arielle
More informationHepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas
Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas Hepatitis C Virus Shimizu et al., 1996 Positive single strand RNA virus Flaviviridae family, Hepacivirus genus 9.6 kbp genome ~3000
More informationFat and Viral Liver Disease
Fat and Viral Liver Disease Francesco Negro Viropathology Unit University of Geneva Medical Center Geneva, Switzerland Mainz, September 20, 2008 Steatosis and HBV Steatosis in HBV infection: prevalence
More informationHepatitis C Glossary of Terms
Acute Hepatitis C A short-term illness that usually occurs within the first six months after someone is exposed to the hepatitis C virus (HCV). 1 Antibodies Proteins produced as part of the body s immune
More informationInnovazione farmacologica e farmacologia clinica
Innovazione farmacologica e farmacologia clinica Francesco Scaglione, MD, PhD Department of Medical Biotechnology and Translational Medicine School of medicine Postgradute School of clinical pharmacology
More informationTG1050, A NOVEL IMMUNOTHERAPEUTIC TO TREAT CHRONIC HEPATITIS B, CAN CONTROL HBsAg AND PROVOKE HBsAg SEROCONVERSION IN HBV-PERSISTENT MOUSE MODELS
TG1050, A NOVEL IMMUNOTHERAPEUTIC TO TREAT CHRONIC HEPATITIS B, CAN CONTROL HBsAg AND PROVOKE HBsAg SEROCONVERSION IN HBV-PERSISTENT MOUSE MODELS Karine Lélu 1, Alexei Evlachev 1, Roland Kratzer 1, Sarah
More informationViruses. Viral components: Capsid. Chapter 10: Viruses. Viral components: Nucleic Acid. Viral components: Envelope
Viruses Chapter 10: Viruses Lecture Exam #3 Wednesday, November 22 nd (This lecture WILL be on Exam #3) Dr. Amy Rogers Office Hours: MW 9-10 AM Too small to see with a light microscope Visible with electron
More informationCASL Symposium Hepatitis B Co-chairs: Carla Coffin and Mang Ma
CASL Symposium Hepatitis B Co-chairs: Carla Coffin and Mang Ma Occult HBV Infection: Assessment and Clinical Significance D. Lorne Tyrrell Director, Li Ka Shing Institute of Virology University of Alberta
More informationCo-infected health-care workers
Co-infected health-care workers Y.Yazdanpanah Service Universitaire des Maladies Infectieuses et du Voyageur C.H. Tourcoing, Faculté de Médecine de Lille CNRS U362, Lille, France Co-infected health-care
More informationCustom Antibody Services
prosci-inc.com Custom Antibody Services High Performance Antibodies and More Broad Antibody Catalog Extensive Antibody Services CUSTOM ANTIBODY SERVICES Established in 1998, ProSci Incorporated is a leading
More informationThe role of IBV proteins in protection: cellular immune responses. COST meeting WG2 + WG3 Budapest, Hungary, 2015
The role of IBV proteins in protection: cellular immune responses COST meeting WG2 + WG3 Budapest, Hungary, 2015 1 Presentation include: Laboratory results Literature summary Role of T cells in response
More informationIdentification of T-cell epitopes of SARS-coronavirus for development of peptide-based vaccines and cellular immunity assessment methods
RESEARCH FUND FOR THE CONTROL OF INFECTIOUS DISEASES PKS Chan 陳 基 湘 S Ma 文 子 光 SM Ngai 倪 世 明 Key Messages 1. Subjects recovered from SARS-CoV infection retain memory of cellular immune response to epitopes
More informationHing wars. During World War II, there was a series of hepatitis outbreaks
Hepatitis C: Toward a Cure and Eradication 1 CHARLES M. RICE Head, Laboratory of Virology and Infectious Disease Scientific and Executive Director Center for the Study of Hepatitis C Rockefeller University
More informationHepatitis C Vaccines: Are we making progress?
Hepatitis C Vaccines: Are we making progress? Second International Hepatitis Cure and Eradication Meeting. Vancouver November, 2015 Objectives: Review the need for a preventive vaccine in 2015. Identify
More informationA novel polarized cell culture model to study HCV infection
A novel polarized cell culture model to study HCV infection Sandrine Belouzard Centre d Infection et d Immunité de Lille 15 ième réunion du réseau national hépatites Paris- 30 janvier 2015 HCV entry and
More informationIntroduction. Genetic variability a major challenge for vaccine development. Abstract Summary
Development of hepatitis C virus vaccines: challenges and progress 1 2 * Françoise Stoll-Keller, Heidi Barth 3, Samira Fafi-Kremer 1 2, Mirjam B. Zeisel 1, Thomas F. Baumert 1 4 1 Interaction virus-hôte
More informationHepatitis C Virus Inactivation
Hepatitis C Virus Inactivation PD Dr. Eike Steinmann Centre for Experimental and Clinical Infection Research Institute of Experimental Virology, Twincore* *joint venture between Medical School Hannover
More informationKMS-Specialist & Customized Biosimilar Service
KMS-Specialist & Customized Biosimilar Service 1. Polyclonal Antibody Development Service KMS offering a variety of Polyclonal Antibody Services to fit your research and production needs. we develop polyclonal
More informationThe immunogenic vaccine against HCV and HBV
National Centre for Research and Development, The immunogenic vaccine against HCV and HBV Katarzyna Grzyb Laboratory of Virus Molecular Biology Intercollegate Faculty of Biotechnology UG-MUG 1 Hepatitis
More informationThe Need for a PARP in vivo Pharmacodynamic Assay
The Need for a PARP in vivo Pharmacodynamic Assay Jay George, Ph.D., Chief Scientific Officer, Trevigen, Inc., Gaithersburg, MD For further infomation, please contact: William Booth, Ph.D. Tel: +44 (0)1235
More informationTRANSGENE SA, FRANCE 2. INSTITUT PASTEUR, FRANCE On behalf. AFEF 2013, Lille 02 nd October 2013
A MULTIVALENT ADENOVIRUS-BASED IMMUNOTHERAPEUTIC FOR TREATMENT OF CHRONIC HEPATITIS B INDUCES BROAD, ROBUST AND POLYFUNCTIONAL T CELLS IN NAIVE MICE AND EXERT AN EARLY ANTIVIRAL EFFECT IN HBV TOLERANT
More informationPositive impact of HCV treatment initiation on health outcomes in injecting drug users
Positive impact of HCV treatment initiation on health outcomes in injecting drug users Perrine ROUX, PhD Substance Use Research Center, Columbia University, NY Inserm U912, SE4S, Marseille Introduction
More informationFIGHTING AIDS AT THE GATE
FIGHTING AIDS AT THE GATE T h e r a m p a n t s p r e a d o f H I V i n f e c t i o n a c r o s s t h e g l o b e i s n o l o n g e r t h e m e d i a c r i s i s o f t h e m o m e n t. B u t A I D S h
More informationGuidance for Industry Antiviral Product Development Conducting and Submitting Virology Studies to the Agency
Guidance for Industry Antiviral Product Development Conducting and Submitting Virology Studies to the Agency U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationViral Replication. Viral Replication: Basic Concepts
Viral Replication Scott M. Hammer, M.D. Viral Replication: Basic Concepts Viruses are obligate intracellular parasites Viruses carry their genome (RNA or DNA) and sometimes functional proteins required
More informationA white paper for consideration by the NIAID Microbial Sequencing Program
Hepatitis C Virus Sequencing: Viral evolution, immune recognition and vaccine development. A white paper for consideration by the NIAID Microbial Sequencing Program Todd M. Allen, Ph.D. Assistant Professor
More informationChapter 5: Organization and Expression of Immunoglobulin Genes
Chapter 5: Organization and Expression of Immunoglobulin Genes I. Genetic Model Compatible with Ig Structure A. Two models for Ab structure diversity 1. Germ-line theory: maintained that the genome contributed
More informationMicroRNA formation. 4th International Symposium on Non-Surgical Contraceptive Methods of Pet Population Control
MicroRNA formation mirna s are processed from several precursor stages Mammalian genomes seem to have 100 s of mirna s Nucleotides in positions 2-8 of an mirna are considered the mirna seed 5 Methyl-G
More informationLiver Disease and Therapy of Hepatitis B Virus Infections
Liver Disease and Therapy of Hepatitis B Virus Infections University of Adelaide Catherine Scougall Arend Grosse Huey-Chi Low Allison Jilbert Fox Chase Cancer Center Chunxiao Xu Carol Aldrich Sam Litwin
More informationRNA Viruses. A Practical Approac h. Alan J. Cann
RNA Viruses A Practical Approac h Alan J. Cann List of protocols page xiii Abbreviations xvii Investigation of RNA virus genome structure 1 A j. Easton, A.C. Marriott and C.R. Pringl e 1 Introduction-the
More informationMid-Clinical Stage Antiviral Drug Development Company
BIOTRON LIMITED (ASX:BIT) Mid-Clinical Stage Antiviral Drug Development Company Investor Update 20 August 2015 Dr Michelle Miller Managing Director +61 412 313329 mmiller@biotron.com.au www.biotron.com.au
More informationStructure and Function of DNA
Structure and Function of DNA DNA and RNA Structure DNA and RNA are nucleic acids. They consist of chemical units called nucleotides. The nucleotides are joined by a sugar-phosphate backbone. The four
More informationHBV DNA < monitoring interferon Rx
Hepatitis B Virus Suspected acute hepatitis >>Order: Acute Unknown hepatitis screen Suspected chronic hepatitis >>Order: Chronic unknown hepatitis screen Acute HBV or Delayed Anti HBs response after acute
More informationChapter 36. Media Directory. Characteristics of Viruses. Primitive Structure of Viruses. Therapy for Viral Infections. Drugs for Viral Infections
Chapter 36 Media Directory Drugs for Viral Infections Slide 23 Slide 27 Slide 29 Zidovudine Animation Saquinavir Mesylate Animation Acyclovir Animation Upper Saddle River, New Jersey 07458 All rights reserved.
More informationViral Safety of Plasma-Derived Products
Viral Safety of Plasma-Derived Products SLIDE 1 This presentation will cover viral validation studies for plasma-derived products. FDA requires that the manufacturing process for biopharmaceutical products
More informationL hépatite virale C en Médecine Familiale- Rurale Montréal-Québec Mai 2015
L hépatite virale C en Médecine Familiale- Rurale Montréal-Québec Mai 2015 Demographics Luis Rivero Pinelo MD LMCC, CCFP, FCFP, Fellow SRPC, CSPQ Shawville- Québec Aux États Unis, la prévalence est présente
More informationGene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press
Gene Therapy The use of DNA as a drug Edited by Gavin Brooks BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Contents Preface xiii Acknowledgements xv About the editor xvi Contributors xvii An introduction
More informationTHÈSE présentée par :
UNIVERSITÉ DE STRASBOURG ÉCOLE DOCTORALE _Sciences de la vie (ED414) [ Institute de virologie, Inserm U748 ] THÈSE présentée par : [ MUHAMMAD NAUMAN ZAHID ] soutenue le : 27 Avril 2012 pour obtenir le
More informationGeneral presentation
Cantacuzino National Institute of Research-Development for Microbiology and Immunology General presentation Cantacuzino National Institute of Research-Development for Microbiology and Immunology (NIRDMIC)
More information01 02 03 04 05 06 Haemophilus influenza 07 08 09 Proc. Natl. Acad. Sci. U.S.A. Proc. Acad. Natl. Sci. U.S.A. Nature Science Anal. Chem. Anal.Chem Nuc. Acids Res Anal. Chem Nature Science Haemophilus influenzae
More informationFinal Review. Aptamers. Making Aptamers: SELEX 6/3/2011. sirna and mirna. Central Dogma. RNAi: A translation regulation mechanism.
Central Dogma Final Review Section Week 10 DNA RNA Protein DNA DNA replication DNA RNA transcription RNA Protein translation **RNA DNA reverse transcription http://bass.bio.uci.edu/~hudel/bs99a/lecture20/lecture1_1.html
More informationApplication of Neutralization Fingerprinting in Antibody Epitope Prediction and Delineating Antibody Recognition in HIV-1 Sera
Application of Neutralization Fingerprinting in Antibody Epitope Prediction and Delineating Antibody Recognition in HIV-1 Sera Gwo-Yu Chuang Structural Bioinformatics Section Vaccine Research Center/NIAID/NIH
More informationNS5B Sequencing and Phenotypic Resistance Assays for HCV Subtypes 1a and 1b
NS5B Sequencing and Phenotypic Resistance Assays for HCV Subtypes 1a and 1b 5th Intl. Workshop on Hepatitis C Resistance & New Compounds Jacqueline Reeves NS5B Resistance Assays for HCV Subtypes 1a and
More informationNatalia Taborda Vanegas. Doc. Sci. Student Immunovirology Group Universidad de Antioquia
Pathogenesis of Dengue Natalia Taborda Vanegas Doc. Sci. Student Immunovirology Group Universidad de Antioquia Infection process Epidermis keratinocytes Dermis Archives of Medical Research 36 (2005) 425
More informationThe public health risk of influenza in pigs recent insights, key knowledge gaps
The public health risk of influenza in pigs recent insights, key knowledge gaps Prof. Kristien Van Reeth Laboratory of Virology, Faculty of Veterinary Medicine, Ghent University, Belgium H1N1, H3N2 and
More informationMolecular Diagnosis of Hepatitis B and Hepatitis D infections
Molecular Diagnosis of Hepatitis B and Hepatitis D infections Acute infection Detection of HBsAg in serum is a fundamental diagnostic marker of HBV infection HBsAg shows a strong correlation with HBV replication
More informationPublikationsliste Claudia Götz
Publikationsliste Claudia Götz 1. Reinhard,B., Götz, C., and Faillard, H.: Synthesis of N-Acetyl-9-Oacetylneuraminic acid α-p-aminophenylthioketoside and its application as ligand in the affinity chromatography
More informationIdentification of Tick-Borne Encephalitis Virus CD4+ and CD8+ T-Cell Epitopes in Vaccinated or Naturally Infected Humans
Identification of Tick-Borne Encephalitis Virus CD4+ and CD8+ T-Cell Epitopes in Vaccinated or Naturally Infected Humans Schwaiger Julia Clinical Institute of Virology 29.06.2009 1 Thank you! Franz X.
More informationWhen B Cells Go Bad: Infection, Inflammation and Chronic B Cell Stimulation
When B Cells Go Bad: Infection, Inflammation and Chronic B Cell Stimulation Karen S. Anderson MD PhD Associate Professor, Biodesign Institute Arizona State University Mayo Clinic Arizona Conflicts of Interest
More informationHSA Consumer Guide. Understanding Vaccines, Vaccine Development and Production. www.hsa.gov.sg November 2009. How a Vaccine Works.
November 2009 Understanding Vaccines, Vaccine Development and Production Vaccines, in general, help protect people from harmful infections before they come in contact with the disease. Vaccines may also
More informationHCV Infection - An Interesting clinical Review
Review Article imedpub Journals http://www.imedpub.com Hepatitis C virus: Why an Enigma? Abstract Hepatitis C virus was identified as a distinct disease from Hepatitis A virus and Hepatitis B virus in
More informationCase Finding for Hepatitis B and Hepatitis C
Case Finding for Hepatitis B and Hepatitis C John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Atlanta, Georgia, USA Division of Viral Hepatitis National Center
More information2.1.2 Characterization of antiviral effect of cytokine expression on HBV replication in transduced mouse hepatocytes line
i 1 INTRODUCTION 1.1 Human Hepatitis B virus (HBV) 1 1.1.1 Pathogenesis of Hepatitis B 1 1.1.2 Genome organization of HBV 3 1.1.3 Structure of HBV virion 5 1.1.4 HBV life cycle 5 1.1.5 Experimental models
More informationLecture 8. Protein Trafficking/Targeting. Protein targeting is necessary for proteins that are destined to work outside the cytoplasm.
Protein Trafficking/Targeting (8.1) Lecture 8 Protein Trafficking/Targeting Protein targeting is necessary for proteins that are destined to work outside the cytoplasm. Protein targeting is more complex
More informationChikungunya: An emerging outbreak from East Africa to Indian Ocean, 2004-2007
Chikungunya: An emerging outbreak from East Africa to Indian Ocean, 2004-2007 A. Flahault, G. Aumont, V Boisson, X de Lamballerie, F. Favier, B.A. Gaüzère, D. Fontenille, S. Journeaux, V. Lotteau, C. Paupy,
More informationF fusion of Cytosolic Droplets and Insulin Resistance to Lung Cancer
Cytosolic lipid droplets: link to the development of insulin resistance and increased production of VLDL1 Sven-Olof Olofsson, MD, PhD Insulin resistance is an important risk factor for the development
More informationLESSON 3: ANTIBODIES/BCR/B-CELL RESPONSES
Introduction to immunology. LESSON 3: ANTIBODIES/BCR/B-CELL RESPONSES Today we will get to know: The antibodies How antibodies are produced, their classes and their maturation processes Antigen recognition
More informationRNAi Shooting the Messenger!
RNAi Shooting the Messenger! Bronya Keats, Ph.D. Department of Genetics Louisiana State University Health Sciences Center New Orleans Email: bkeats@lsuhsc.edu RNA interference (RNAi) A mechanism by which
More informationTreatment Options for Hepatitis C in the Post Transplant Patient
Treatment Options for Hepatitis C in the Post Transplant Patient Caroline Rochon, MD, FACS,FRCSC Transplant and Hepatobiliary Surgery Hartford Hospital Assistant Professor of Surgery, University of Connecticut
More informationImmunity and how vaccines work
1 Introduction Immunity is the ability of the human body to protect itself from infectious disease. The defence mechanisms of the body are complex and include innate (non-specific, non-adaptive) mechanisms
More informationHepatitis C virus (HCV), the causative agent of hepatitis C,
Recombinant Hepatitis C Virus Envelope Glycoprotein Vaccine Elicits Antibodies Targeting Multiple Epitopes on the Envelope Glycoproteins Associated with Broad Cross-Neutralization Jason Alexander Ji-Xhin
More informationRequired Text: Tortora, Funke, and Case. Microbiology, An Introduction, 9 th ed. Benjamin Cummings, 2007.
Department of Biology Introduction to Microbiology Biol 132 (3 credit hours) Dr. Kathryn Sutton, Assistant Professor of Biology Spring, 2007 M 9-9:50; CBH Room 203 General Information Office Location CBH
More informationBioMmune Technologies Inc. Corporate Presentation 2015
BioMmune Technologies Inc Corporate Presentation 2015 * Harnessing the body s own immune system to fight cancer & other autoimmune diseases BioMmune Technologies Inc. (IMU) ABOUT A public biopharmaceutical
More informationChapter 20: Antimicrobial Drugs
Chapter 20: Antimicrobial Drugs 1. Overview of Antimicrobial Drugs 2. Antibacterial Drugs 3. Antiviral Drugs 4. Drugs for Eukaryotic Pathogens 1. Overview of Antimicrobial Drugs Antibiotics An antibiotic
More informationPopulation Pharmacokinetics of Atazanavir in Naïve HIV Infected Patients using Medication Events Monitoring System (MEMS) for drug intake timing
Population Pharmacokinetics of Atazanavir in Naïve HIV Infected Patients using Medication Events Monitoring System (MEMS) for drug intake timing ANRS -COPHAR clinical trial Céline Verstuyft Pharmacologie,
More informationHuCAL Custom Monoclonal Antibodies
HuCAL Custom Monoclonal HuCAL Custom Monoclonal Antibodies Highly Specific, Recombinant Antibodies in 8 Weeks Highly Specific Monoclonal Antibodies in Just 8 Weeks HuCAL PLATINUM (Human Combinatorial Antibody
More informationUnderstanding the immune response to bacterial infections
Understanding the immune response to bacterial infections A Ph.D. (SCIENCE) DISSERTATION SUBMITTED TO JADAVPUR UNIVERSITY SUSHIL KUMAR PATHAK DEPARTMENT OF CHEMISTRY BOSE INSTITUTE 2008 CONTENTS Page SUMMARY
More informationViral Infection: Receptors
Viral Infection: Receptors Receptors: Identification of receptors has come from expressing the gene for the receptor in a cell to which a virus does not normally bind -OR- By blocking virus attachment
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More information20.3 Diseases Caused by Bacteria and Viruses
20.3 Diseases Caused by Bacteria and Viruses Lesson Objectives Explain how bacteria cause disease. Explain how viruses cause disease. Define emerging disease and explain why emerging diseases are a threat
More informationSYMPOSIUM. June 15, 2013. Photonics Center Colloquium Room (906) 8 Saint Mary's St., Boston, MA 02215 Boston University
SYMPOSIUM June 15, 2013 Photonics Center Colloquium Room (906) 8 Saint Mary's St., Boston, MA 02215 Bette Korber Los Alamos National Labs HIV evolution and the neutralizing antibody response We have recently
More informationMedical publications on HBV and HCV Coinfection
Recent advances of HBV and HCV co-infection 台 中 榮 總 內 科 部 胃 腸 肝 膽 科 呂 宜 達 醫 師 2013.03.28 Outline Epidemiology of HBV and HCV coinfection Clinical significance of HBV and HCV coinfection Interplay between
More informationEnveloped Virus Like Particles: Third-generation VLPs for the Development of a Broadly Neutralizing Hepatitis C Vaccine
Enveloped Virus Like Particles: Third-generation VLPs for the Development of a Broadly Neutralizing Hepatitis C Vaccine World Vaccine Congress Asia June 2015 Forward-Looking Statement Disclaimer This presentation
More informationMicro RNAs: potentielle Biomarker für das. Blutspenderscreening
Micro RNAs: potentielle Biomarker für das Blutspenderscreening micrornas - Background Types of RNA -Coding: messenger RNA (mrna) -Non-coding (examples): Ribosomal RNA (rrna) Transfer RNA (trna) Small nuclear
More informationHEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis
HEPATITIS WEB STUDY Acute C Virus Infection: Epidemiology, Clinical Features, and Diagnosis H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School
More informationCommonly Asked Questions About Chronic Hepatitis C
Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral
More informationJoão Silva de Mendonça, MD, PhD Infectious Diseases Service Hospital do Servidor Público Estadual São Paulo - Brazil
Brazilian Ministry of Health, Brazilian Society of Hepatology PAHO, Viral Hepatitis Prevention Board PART III SESSION 9 Prevention and control of Viral Hepatitis in Brazil HEPATITIS IN SPECIAL RISK GROUPS/
More informationNoam Danenberg CEO N. Danenberg Holding Ltd noam@danenberg.co.il
Noam Danenberg CEO N. Danenberg Holding Ltd noam@danenberg.co.il Experience CEO at N. Danenberg Holding (2000) Ltd) 2000 - Present (13 years) Investment Consulting Firm Consultant at Bonzai Holding Ltd.
More informationD Candotti. Institut National de la Transfusion Sanguine Dept. Agents Transmissibles par le Sang Paris, France
Molecular characterization of hepatitis B virus strains infecting blood donors with high HBsAg and undetectable HBV DNA levels: implications for blood safety and screening policy D Candotti Institut National
More informationELISA BIO 110 Lab 1. Immunity and Disease
ELISA BIO 110 Lab 1 Immunity and Disease Introduction The principal role of the mammalian immune response is to contain infectious disease agents. This response is mediated by several cellular and molecular
More informationCourse Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology
Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology The Master Degree in Medical Laboratory Sciences / Clinical Microbiology, Immunology or
More informationDiabetes and Drug Development
Diabetes and Drug Development Metabolic Disfunction Leads to Multiple Diseases Hypertension ( blood pressure) Metabolic Syndrome (Syndrome X) LDL HDL Lipoproteins Triglycerides FFA Hyperinsulinemia Insulin
More informationCHAPTER 9 IMMUNOGLOBULIN BIOSYNTHESIS
CHAPTER 9 IMMUNOGLOBULIN BIOSYNTHESIS Although the process by which a functional gene for immunoglobulin HEAVY and LIGHT CHAINS is formed is highly unusual, the SYNTHESIS, POST- TRANSLATIONAL PROCESSING
More informationLIAISON XL HCV Ab Accurate diagnosis of the early stage of HCV infection
Hepatitis and Retrovirus LIAISON XL HCV Ab Accurate diagnosis of the early stage of HCV infection FOR OUTSIDE THE US AND CANADA ONLY LIAISON XL HCV Ab is Your solution LIAISON XL murex HCV Ab main features
More informationLA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti. Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova
LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova HBV ed HCV Due virus Diversi ma con molte Cose in Comune
More informationVaccines Researches for the Future:
ITMO Microbiologie et maladies infectieuses Vaccines Researches for the Future: The corevac initiative Pr Brigitte AUTRAN Institute Infection-Cancer-Immunity, UPMC, Paris Pr Jean François Delfraissy Institute
More informationName Date Period. 2. When a molecule of double-stranded DNA undergoes replication, it results in
DNA, RNA, Protein Synthesis Keystone 1. During the process shown above, the two strands of one DNA molecule are unwound. Then, DNA polymerases add complementary nucleotides to each strand which results
More informationAERES report on the research unit
Section des Unités de recherche AERES report on the research unit Fonction structure et inactivation d ARN bactériens From the University Rennes 1 INSERM December 2010 Section des Unités de recherche AERES
More information1 2 3 4 5 6 Figure 4.1: Gel picture showing Generation of HIV-1subtype C codon optimized env expressing recombinant plasmid pvax-1:
Full-fledged work is in progress towards construction and cloning of codon optimized envelope with subsequent aims towards immunization of mice to study immune responses. 1 2 4 5 6 Figure 4.1: Gel picture
More informationChapter 8. Summary and Perspectives
Chapter 8 Summary and Perspectives 131 Chapter 8 Summary Overexpression of the multidrug resistance protein MRP1 confer multidrug resistance (MDR) to cancer cells. The contents of this thesis describe
More informationBIOMEDICAL SCIENCES GRADUATE PROGRAM AUTUMN 2015
THE OHIO STATE UNIVERSITY BIOMEDICAL SCIENCES GRADUATE PROGRAM AUTUMN 2015 Sara M. Johnson PhD Candidate Respiratory Syncytial Virus Uses CX3CR1 as a Cellular Receptor on Primary Human Airway Epithelial
More informationWhen an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII)
XI. OCCUPATIONAL EXPOSURES TO HEPATITIS B AND C RECOMMENDATION: When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII) The risk of transmission
More informationImpact of Hepatitis C Virus NS5A Genetic Variability on Liver Pathogenesis and Viral Replication
Thèse présenté pour obtenir le grade de Docteur de l Université Paris Est-Créteil Spécialité : Aspects Moléculaires et Cellulaires de le Biologie par Muhammad Ahmad MAQBOOL Impact of Hepatitis C Virus
More informationboceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationCompartmentalization of the Cell. Objectives. Recommended Reading. Professor Alfred Cuschieri. Department of Anatomy University of Malta
Compartmentalization of the Cell Professor Alfred Cuschieri Department of Anatomy University of Malta Objectives By the end of this session the student should be able to: 1. Identify the different organelles
More informationCHARACTERIZATION OF RABBIT MONOCLONAL ANTIBODIES PRODUCED BY AN HIV-1 VACCINE
MQP-BIO-DSA-7964 CHARACTERIZATION OF RABBIT MONOCLONAL ANTIBODIES PRODUCED BY AN HIV-1 VACCINE A Major Qualifying Project Report Submitted to the Faculty of the WORCESTER POLYTECHNIC INSTITUTE in partial
More information10. T and B cells are types of a. endocrine cells. c. lymphocytes. b. platelets. d. complement cells.
Virus and Immune System Review Directions: Write your answers on a separate piece of paper. 1. Why does a cut in the skin threaten the body s nonspecific defenses against disease? a. If a cut bleeds, disease-fighting
More informationImmune Epitope Database NEWSLETTER Volume 7, Issue 1 http://www.iedb.org March 2010
Immune Epitope Database NEWSLETTER Volume 7, Issue 1 http://www.iedb.org March 2010 IEBD 2.3 Released January 19 The latest version of the IEDB website was released on January 19. A list of the new features
More information